Table 1.
Characteristics of trials included in systematic review.
| Author/year/place of trial/type of trial | Participants | Intervention | Duration of study (months) | |
|---|---|---|---|---|
| 1 | Malekzadeh et al (2010), Iran, Double blind placebo controlled parallel group trial |
Men (age 50–79), women (age 55–79) No diagnosed CVD, not taking any antihypertensive medications or statins | Pollypill group (one Pollypill containing aspirin 81 mg, enalapril 2.5 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg) (n = 241) Placebo group (similar looking placebo) (n = 234) |
12 |
| 2 | Yusuf et al (2012) (Multicentric, India) Double blind parallel group trial |
Men and women >40 year with previous vascular disease or diabetes mellitus | Full dose group (two capsule each containing simvastatin 20 mg, ramipril 5 mg, atenolol 50 mg, hydrochlorothiazide 12.5 mg, and aspirin 100 mg) with potassium 30 mEq/L (n = 257) Low dose group (two capsules; one containing simvastatin 20 mg, ramipril 5 mg, atenolol 50 mg, hydrochlorothiazide 12.5 mg, aspirin 100 mg, and another cap and one capsule is similar looking placebo) (n = 261) |
2 |
| 3 | Soliman et al (2011) (Muticentric, Sri Lanka) Parallel group open label trial |
Men aged > 40 years and women > 50 years 10-year CVD risk score > 20% | Pollypill group (75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril, and 12.5 mg hydrochlorothiazide) (n = 99) Standard practice (n = 104) |
3 |
| 4 | PILL Collaborative Group (2011) (Multicentric, international) Double blind placebo controlled parallel group trial |
Men and women aged > 18 years Cardiovascular risk over 5years > 7.5% | Pollypill group (aspirin 75 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg, and simvastatin 20 mg) (n = 189) Placebo – identical pill (n = 189) |
|
| 5 | Wald et al (2012) Double blind placebo controlled cross over trial |
Men and women aged > 50 years No self reported cardiovascular event Already taking simvastatin or BP lowering drug in cardiovascular preventive program | Pollypill group (amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg) (n = 84) Placebo – identical pill (n = 84) |
3 |
| 6 | The Indian Polycap Study (TIPS) Investigators (2009) (Multicentric, India) Double blind parallel group trial |
Men and women aged > 45 years and < 08 year without cardiovascular disease, having atleast one risk factor | Pollypill (thiazide 12.5 mg, atenolol 50 mg, ramipril 5 mg, simvastatin 20 mg, and aspirin 100 mg) (n = 412) Aspirin (n = 205) Thiazide (n = 205) Thiazide + ramipril (n = 209) Thiazide + atenolol (n = 207) Ramipril + atenolol (n = 205) Thiazide + ramipril + atenolol (n = 204) Thiazide + ramipril + atenolol + aspirin (n = 204) Simvastatin (n = 202) |
3 |